Rhythm Pharmaceuticals Inc.

#ICYMI We recently announced the publication of results from our Phase 3 study in children between the ages of 2 and younger than 6 years old with Bardet Biedl syndrome (BBS) or pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency in the peer-reviewed journal The Lancet Diabetes & Endocrinology. Read our press release to learn more: https://bit.ly/40NKvkQ

Rhythm is committed to advancing genetic understanding to further MC4R pathway research and disease knowledge, and to help foster a community focused on learning more. Learn more about our research and development efforts here: https://lnkd.in/ezGgWm6S #raredisease

Thank you to The Obesity Society for hosting a successful #ObesityWeek earlier this month! We enjoyed sharing our latest updates in the rare neuroendocrine disease space and engaging with other researchers and clinicians to learn about the latest advances in obesity medicine. #OW2024

Last week we announced the publication of results from our Phase 3 study in children between the ages of 2 and younger than 6 years old with Bardet Biedl syndrome (BBS) or pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency in the peer- reviewed journal The Lancet Diabetes & Endocrinology. Thank you to the patients, caregivers, study authors and physician investigators whose important contributions to this research have helped deepen the understanding of these rare neuroendocrine diseases associated with the MC4R pathway, #hyperphagia and severe #obesity. See our press release for details: https://bit.ly/40NKvkQ

At Rhythm, we’re driven to help improve the lives of patients living with rare neuroendocrine diseases by advancing science, developing innovative therapies, and providing unparalleled dedication. Interested in learning more? Check out our current job openings: https://lnkd.in/ejR3hmtZ #JoinUs #Biotech #Hiring

We are excited to attend The European Society for Paediatric Endocrinology’s 62nd Annual ESPE Meeting from November 16-18 in Liverpool! The Rhythm team is looking forward to connecting with peers and endocrinology leaders. #ESPE2024

At Rhythm, we’re pioneering a path forward for patients living with rare neuroendocrine diseases. Learn more about our path to transforming the care of rare MC4R pathway diseases and what makes our company so unique: https://lnkd.in/eUbKrpyD #raredisease

Rhythm President and CEO David Meeker, M.D., will participate in a fireside chat at the Stifel 2024 Healthcare Conference on Monday, November 18, at 11:30 a.m. ET. Learn more here: https://bit.ly/3YH16nC

At Rhythm, we know that all obesity is not the same. The MC4R pathway plays an important role in the underlying biology of food intake and energy burn #obesity and #hyperphagia. Learn more about the science behind MC4R pathway diseases: https://rhythmtx.com/mc4r

Rhythm President and CEO David Meeker, M.D., will discuss Rhythm’s efforts to transform the care of patients with rare neuroendocrine diseases during a fireside chat at the Guggenheim Securities Healthcare Innovation Conference on Monday, Nov. 11, at 11:30 a.m. ET. Learn more here: https://bit.ly/3YH16nC